Меню
КартаВръзкиТемиБългарияНощта (K-TRIO)Мария Склодовска-КюриЗа ученициЗа учителиМетодологияИзненадай ме
H2020Докторантска мрежа2015–2019

RADIATE · Radiation Innovations for Therapy and Education

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период
2015-03-01 → 2019-02-28
Финансиране от ЕС
3 081 061 €
Участници
14
Схема
MSCA-ITN-ETN

Линиите свързват координатора с партньорите.

Накратко на български

Радиобиологията изследва причините за устойчивостта на туморите към лъчетерапия и чувствителността на здравите тъкани. По-доброто разбиране на тези процеси помага за подобряване на резултатите от лечението при рак.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Radiation Innovations for Therapy and Education

45-60% of all cancer patients are treated with radiotherapy (RT). Some patients recover completely, but unfortunately in other cases their cancer is not cured. This may result from the outgrowth of distant metastases, but commonly it may also result from regrowth of the primary tumor. There is a clear need for further research in this field. This Innovative Training Network (ITN) is built on the premise that advances in understanding radiobiology will open novel routes to improve patient outcomes, and that such progress requires a Europe-wide effort. RADIATE brings together a consortium of radiobiologists, clinicians and scientists, from seven European academic Institutes. These researchers have experience in developing novel strategies to improve radiation therapy for cancer, and in providing training for the next generation of researchers to better the outcome of cancer therapy. Since translation of basic scientific research into the clinic frequently requires commercial participation, this ITN included industrial partners with expertise in developing novel reagents, biomarkers and drugs that could be used, in combination with radiation, for cancer therapy. This European network stimulated outstanding science, thereby enhancing Europe´s competitive capability in this highly relevant but still under-represented and fragmented research area. The Early Stage Researchers (ESRs) and the partners all benefitted from scientific exchange and interactions across the networks’ research and training events. The failure to eliminate the cancer at its primary site can be placed into two general categories: 1) radioresistance of the tumor and the sensitivity of surrounding normal tissue; 2) the effects of the tumor microenvironment leading to greater overall resistance and altering the immune response to the tumor. Exploration of these two categories formed our first two work packages (WP), with translational work designed to identify and implement new therapeutic strategies for use in RT, being the third.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Approximately 45-60% of all cancer patients are treated with radiotherapy. Some of these patients have a good outcome, but in other cases their illness fails to be cured. This may result from distant metastases or from regrowth of the primary tumor. This training network is built on the premise that considerable advances in understanding radiobiology will open novel routes for effective therapeutic intervention with biological targets to improve the outcome of cancer treatment; this progress requires a European-wide effort. This network of radiobiologists, clinicians and scientists with complementary expertise will stimulate outstanding science, meeting the high demand for excellent young academics enhancing Europe´s competitive capability in this highly relevant but underrepresented and fragmented research area. We will strengthen collaborations and technological platforms to develop effective therapeutic strategies for cancer. The failure to eliminate the primary cancer can be placed into 2 categories: the radioresistance of the tumor and the sensitivity of surrounding normal tissue; and the effects of the tumor microenvironment leading to greater overall resistance and altering the immune response to the tumor. This will be combined with translational work designed to identify and implement new therapeutic strategies for use in radiotherapy. Students will benefit from the expertise of the whole, both academic and industrial including unique research technologies that will now be available throughout the network, including a variety of screening platforms, methodology for preclinical cancer therapy and novel radiation and imaging technologies. The European community will benefit from the pursuit of innovative hypotheses, training of new researchers, and dissemination of knowledge. By combating a major death-related disease in Europe this project will raise health and bring long-term benefit to the European and international community.

Оригинален текст от CORDIS (на английски).

Участници

Връзки

Данни: CORDIS, © Европейски съюз